MZF1 and familial pancreatic carcinoma: These data suggest that SCAND1-MZF1 high expression is a better prognosis marker for patients suffering from pancreatic cancer and head and neck cancers, whereas SCAND1-MZF1 high expression is a poorer prognosis marker for patients suffering from kidney cancer.